Description
This program reviews key updates from the 2026 ADA Standards of Care in Diabetes, focusing on optimizing insulin delivery for people with diabetes requiring prandial insulin. It will discuss treatment modalities—including automated insulin delivery (AID), multiple daily injections (MDI), and inhaled insulin—while emphasizing individualized, person-centered decision-making.
Participants will explore ongoing unmet needs in mealtime insulin use, including glycemic variability, hypoglycemia, medication taking challenges, and quality-of-life impact, and assess how inhaled insulin may help address gaps through its rapid pharmacokinetics and ease of use.
The session also provides practical guidance on clinical implementation, including patient selection, dosing, titration, and key pulmonary safety considerations to support confident integration into practice.
Learning Objectives
After attending this webinar, participants will be able to:
1. Apply 2026 ADA Standards to optimize prandial insulin therapy and delivery (AID, MDI, inhaled insulin).
2. Identify unmet needs in mealtime insulin use and evaluate the role of inhaled insulin in improving glycemic management, convenience, and persistent insulin taking.
3. Implement inhaled insulin in practice, including patient selection, dosing, titration, and pulmonary safety.
Sponsor
This webinar is sponsored by MannKind.
Disclaimer
There is no CE/CME credit for this activity.
Access Period
You will have access to this learning activity for a period of six months after you enroll, or whenever the activity expires (whichever comes first).
Originally presented on: 6/16/2026
Expiration date: 6/16/2028